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Summary
Thrombocytopenia is a condition characterized by extremely low platelet counts, which puts
patients at elevated risk of morbidity and mortality because of bleeding. Trials in transfusion
medicine are routinely designed to assess the effect of experimental platelet products on patients
platelet counts. In such trials, patients may receive multiple platelet transfusions over a predefined
period of treatment, and a response is available from each such administration. The resulting data
comprised multiple responses per patient, and although it is natural to want to use this data in test-
ing for treatment effects, naive analyses of the multiple responses can yield biased estimates of the
probability of response and associated treatment effects. These biases arise because only subsets
of the patients randomized contribute response data on the second and subsequent administrations
of therapy and the balance between treatment groups with respect to potential confounding factors
is lost. We discuss the design and analysis issues involved in this setting and make recommenda-
tions for the design of future platelet transfusion trials.
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1 INTRODUCTION
1.1 PLATELET TRANSFUSION TRIALS IN THROMBOCYTOPENIA
Thrombocytopenia is a chronic medical condition characterized by abnormally low platelet counts in
which patients are at significant risk of morbidity and mortality due to bleeding [1]. The causes of
thrombocytopenia are multifaceted and include immunological abnormalities [2], treatment with anti-
coagulants in orthopedic surgery patients [3], infection [4], and exposure to certain medications such
as methotrexate [5]. It also arises in patients with cancer or hematologic disorders as a consequence
to chemotherapy [6]. Treatment often includes prednisone, infusions of intravenous immunoglobulin,
and platelet transfusion [7]. Platelet transfusion, however, can lead to antibody responses in recipi-
ents, and as a result, there has been considerable research directed at the development of pathogen-
inactivated platelet products to reduce the risks of these reactions [8–13]. This article is concerned
with methodological challenges arising in the design and analysis of randomized trials directed at
comparing the effectiveness of standard and pathogen inactivated platelets.
While the ultimate goal of platelet transfusion is to reduce the risk of bleeding, hemorrhagic events
are fairly rare and there are challenges in how best to summarize bleeding outcome data and make
associated treatment comparisons [14–16]. As a result, trials typically examine the effect of a platelet
transfusion in terms of the change in the recipients platelet count before and after the transfusion,
called the count increment. When this difference is standardized with respect to body mass and the
dose of platelets transfused, the resulting measure is called the corrected count increment (CCI), and
this is perhaps the most common response adopted in randomized trials of platelet products [17]. The
post-transfusion platelet counts are measured at different times in different studies, but in European
studies, blood samples are often taken 1 h after the transfusion, in which case, the associated CCI
reflects the short term effect of the transfusion. The CCI can be used as a continuous response or
dichotomized; 1 h CCI values above 7500 (×106 m2/`) represent “successful” transfusions.
The timing and need for transfusions vary considerably between patients because of differences
in the severity of the underlying condition, the schedule and intensity of chemotherapy, and other
known and unknown factors. Protocols often dictate that data on the responses to a pre-specified
number of transfusions are to be analysed [9]. If all patients are followed until they experience the
pre-specified number of transfusions, then this is a reasonable strategy. Under suitable assumptions,
there are obvious efficiency gains from using data beyond the first transfusion, and data over the
broader course of treatment may be viewed as more reflective of the overall burden of disease and
benefit of transfusion therapy. In most settings however, there is a fixed period of treatment (e.g.,
4 weeks) and the number of transfusions required over this time period will be random and may be
far lower than the prespecified number. This is further complicated by the fact that the number of
transfusions administered in a fixed window of time is potentially related to the platelet product to
which patients have been assigned, the response to the intervention, and observed and unobserved
covariates. In this case, standard use of data beyond the first administration is problematic because
the balance in the distribution of potential confounding variables between treatment arms is lost for
second and subsequent transfusions. In essence, marginal treatment comparisons based on the second
administration of platelet therapy are based only on those patients requiring a second administration
and thus constitutes an improper subgroup comparison [18].
In this article, we discuss particular models for the transfusion process, and study the biases
resulting from standard longitudinal analyses. We discuss ways to analyse the data from such a
study, which permit causal inference using a simple marginal model, investigate the performance
of the methods through simulation studies, and illustrate their use through application to data from a
motivating trial. We organized the remainder of this paper as follows. In Section 2, we define notation
and formulate models for the need for transfusions and the response to transfusions. In Section 3, we
highlight the effect of confounding in the second and subsequent transfusions by deriving limiting
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values of parameters obtained from naive analyses. In Section 4, we conduct simulation studies
to point out how marginal models can be fitted using weights to adjust for the effect of confounders
arising, despite the initial randomization, from the finite period of observation. We give an application
to a recent platelet transfusion trial for illustration. We make general remarks in Section 5.
1.2 THE MIRASOL TRIAL OF PATHOGEN-INACTIVED PLATELETS
Cazenave et al. [11] report on a recent multicentre trial of 118 hematology/oncology patients with
chemotherapy-induced thrombocytopenia who were randomized to receive either pathogen-inactivated
platelets (Mirasol) or standard platelets as required over a 28 day treatment period. The primary out-
come in this trial was the CCI with the posttransfusion platelet count measured 1 hour after trans-
fusion. The protocol stipulated that CCI responses from a maximum of eight transfusions occurring
over the 28 day treatment period would be used for each patient in the assessment of the experimental
and reference products. The primary analysis is based on comparing the probability of successful
response between treatment arms under the implicit assumption that this probability does not change
over time within treatment groups.
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Figure 1: Sample timeline plots of platelet transfusions and associated 1 h corrected count increments
for four individuals from the Mirasol study [11] ; the horizontal line at 7500 is the threshold for
defining successful responses to transfusion.
Cazenave et al. [19] give the rationale for restricting attention to eight transfusions, and this is now
common practice in such studies. In examining data from an earlier platelet transfusion trial, when
considering all transfusions received, there was considerable heterogeneity in the mean CCI between
patients such that there was a tendency for the mean CCI response per transfusion to be higher among
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patients who had a smaller number of transfusions. Restricting the number of transfusions used in the
analysis to a maximum of eight was put forward as one method for reducing the heterogeneity. It is
important, however, to consider the source of this heterogeneity. Poor response (low CCI) to a trans-
fusion means a patient’s platelet count remained low and they are therefore at relatively higher risk of
needing subsequent transfusions. In contrast, if a patient has a large CCI from a particular transfusion,
there will likely be a longer time to the next transfusion. This could explain the association between
the mean CCI per patient and the number of transfusions they require in any given treatment period.
Figure 1 displays data for a sample of four patients from the Mirasol study. The vertical axis is
the CCI, and the horizontal axis indicates the number of days since randomization. The height of
the vertical lines reflect the 1 h CCI, and the horizontal dashed line at 7500 is the threshold defining
successful (CCI > 7500) or unsuccessful (CCI ≤ 7500) transfusions. Patient 1 required only two
transfusions during the 28 day treatment period, and both led to large increases in the platelet counts
satisfying the definition of a successful response. Patient 4, on the other hand, required twelve trans-
fusions, and only one of these led to a successful response. Patients 2 and 3 had intermediate numbers
of transfusions, which were of mixed success.
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Figure 2: Plots of the empirical cumulative distribution functions for the 1 h corrected (CCI) for the
first five transfusions for individuals in the control group (the number of subjects contributing to these
estimates are indicated in the legend).
As stipulated in the protocol, secondary analyses were directed at the assessment of trend in the
probability of response by transfusion number. There are difficulties in assessing success rates by
transfusion number because of selection effects arising from the finite treatment period. Figure 2
which contains the empirical distribution functions for the 1 hour CCI for the first five transfusions
among all relevant patients in the control arm, illustrates an apparant trend. A naive interpretation of
the plots suggest a trend toward a decreasing median CCI with increasing transfusion number. The
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Figure 3: Schematic illustrating the relationship between the different post-randomization variables
for a hypothetical individual; on the horizontal axis, open and closed circles correspond to days of
unsuccessful and successful platelet transfusions, respectively.
vertical line at 7500 can be used to estimate the empirical success rates, which are not inconsistent
with a decreasing success rate with increasing transfusion number. The legend indicates the decreas-
ing number of patients contributing to these estimates, which suggests the possibility of a selection
effect driving the apparent trend. We aim to describe strategies for removing this potentially spurious
signal of trend, after first formulating a model, which can be used to mimic this phenomenon.
2 NOTATION AND MODEL FORMULATION
2.1 NOTATION
Let X = 1 if an individual has been randomized to receive the experimental platelet product and
X = 0 otherwise, where P (X = 1) = 0.5. For simplicity, we consider a single additional binary
covariate V , which may be a confounder or effect modifier; we let V = 1 indicate the presence
of a factor and V = 0 otherwise, and let P (V = 1) = expit(ν). We focus on a discrete time
stochastic process {Z(t), 0 < t} for the need for transfusion, where time t is the number of days
since randomization; the variable Z(t) = 1 if an individual receives a transfusion on day t and is zero
otherwise. The history for the transfusion process at time t is Z¯(t) = {Z(1), . . . , Z(t − 1)}, which
records the number and timing of transfusions up to and including day t − 1. Additional variables
related to {Z(s), 0 < s} include N(t), which records the cumulative number of transfusions over
(1, t], and Tk, which is the day of the kth transfusions, k = 1, . . . Upon receiving the kth transfusion,
we may classify a response as successful, indicated by Yk = 1, or unsuccessful, indicated by Yk = 0.
We denote the history for the outcomes of all transfusions prior to time t by Y¯ (t) = {Y1, . . . , YN(t−1)}
and we let Y¯k = {Y1, . . . , Yk−1} denote the responses to the first k − 1 transfusions. We denote the
full history at time t is denoted H¯(t) = {Y¯ (t), Z¯(t), X, V }, which includes information on the fixed
covariates. Figure 3 contains a schematic diagram demonstrating the meaning of the variables related
to the transfusion process, where open and closed circles on the horizontal axis indicate unsuccessful
and successful platelet transfusions, respectively.
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2.2 A MODEL FOR THE TRANSFUSION PROCESS
At the time of the first transfusion, we randomize individuals to a treatment arm, which dictates the
platelet product that will be used for the initial and subsequent transfusions. Because all individuals
have transfusions on day 1, P (Z(1) = 1) = 1, but for subsequent days, we require a probability
model. We adopt a model on the basis of the discrete intensity λ(t|H¯(t)) = P (Z(t) = 1|H¯(t)),
1 < t, which is the conditional probability of requiring a transfusion on day t given the full history.
The key features of the history governing the need for transfusions could include, for example, the
risk factor V , whether a transfusion was given on the previous day (Z(t − 1)), platelet product (X),
and whether the most recent transfusion was successful (YN(t−1)). In this case, we could write the
intensity in the form of a logistic regression model as
λ(t|H¯(t)) = expit(ζ0 + ζ1 V + ζ2 Z(t− 1) + ζ3X + ζ4YN(t−1)) . (2.1)
Other formulations are of course possible, and we can easily incorporate a dependence on more
aspects of the process history.
2.3 A MODEL FOR THE RESPONSE PROCESS
Let K denote the maximum number of transfusions to be analysed in the primary analyses, and let
Y = (Y1, . . . , YK)
′ denote the multivariate response vector. Clinical interest lies in assessing the
effect of the platelet product on the probability of a successful transfusion, and we adopt a model
with a marginal mean, which does not depend on the stage of the transfusion process to ensure it is
compatible with this objective. Thus, given X and V , we take Y to be a vector of Bernoulli variates
with mean pi(X, V ) = (pi1(X, V ), . . . , piK(X, V )), where pik(X, V ) = E(Yk|X, V ). We may let
pik(X, V ) = expit(ϑ0 + ϑ1X + ϑ2V + ϑ3XV ) , (2.2)
for example, to reflect the setting in which individuals with different values of V will experience
different effects of treatment. We let COV(Y |X, V ) = Σ(X, V ) be a K × K matrix comprised
variances
VAR(Yk|X, V ) = pik(X, V )(1− pik(X, V ))
along the diagonal and covariances
COV(Yj, Yk|X, V ) = P (Yj = 1, Yk = 1|X, V )− pij(X, V )pik(X, V ) , (2.3)
in the off-diagonal entries. We denote the conditional odds ratio associating the responses from the
jth and kth transfusions given X and V by
ϕ =
P (Yj = 1, Yk = 1|X, V )/P (Yj = 0, Yk = 1|X, V )
P (Yj = 1, Yk = 0|X, V )/P (Yj = 0, Yk = 0|X, V ) .
We assumed an exchangable odds ratio here, but other structures are of course possible. We obtain
the joint probability in (2.3) as
P (Yj = 1, Yk = 1|X, V ) =
{
c(X,V )−[c(X,V )2−4ϕ(ϕ−1)pij(X,V )pik(X,V )]
1/2
2(ϕ−1) if ϕ 6= 1
pij(X, V )pik(X, V ) if ϕ = 1 ,
where c(X, V ) = 1− (1− ϕ)(pij(X, V ) + pik(X, V )) [20].
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2.4 MARGINAL MODELS FOR THE ASSESSMENT OF TREATMENT EFFECTS IN RANDOMIZED
TRIALS
We introduce the variable V to capture variation in the need for transfusions in (2.1) and variation in
the probability of a successful response to a transfusion in (2.2). Protocols of most randomized trials,
however, typically dictate that analyses of treatment effects be based on simple comparisons in which
V is omitted from the response model. If the marginal mean conditional on (X, V ) is given by (2.2)
for example, but we fit a model
P (Yk = 1|X) = expit(θ0 + θ1X) . (2.4)
We can derive θ in terms of ϑ and ν through
P (Yk = 1|X; θ) = EV |X [P (Yk = 1|X, V )] =
1∑
v=0
P (Yk = 1|X, V = v;ϑ)P (V = v; ν) .
Randomization at the point of recruitment justifies the use of P (V ) rather than P (V |X) in the equa-
tion above. Because the true marginal probabilities are independent of k, the values of θ = (θ0, θ1)′
do not depend on k, and we simply have
θ0(ϑ, ν) = logit(P (Yk = 1|X = 0;ϑ, ν)) (2.5a)
θ1(ϑ, ν) = logit(P (Yk = 1|X = 1;ϑ, ν))− θ0(ϑ, ν) . (2.5b)
In this framework the causal parameter of interest is θ1, which represents the log odds ratio for a
successful response to transfusion with X = 1 versus X = 0, averaged over V .
We can obtain the covariance matrix of Y |X on the basis of P (Yj = 1, Yk = 1|X) = EV |X [P (Yj =
1, Yk = 1|V,X)], which is
1∑
v=0
P (Yj = 1, Yk = 1|V = v,X;ϑ, ϕ) P (V = v; ν) .
Given this,
COV(Yj, Yk|X) = P (Yj = 1, Yk = 1|X)− P (Yj = 1|X) P (Yk = 1|X) (2.6)
and we obtain an exchangable association structure with the odds ratio associating Yj and Yk given
only X , as
φ(ϑ, ϕ, ν) =
P (Yj = 1, Yk = 1|X)/P (Yj = 0, Yk = 1|X)
P (Yj = 1, Yk = 0|X)/P (Yj = 0, Yk = 0|X) . (2.7)
It is important to note that these measures of association are different than those of Section 2.3 because
of the omission of the effect modifier V from the response model. In the context of a randomized trial,
one can legitimately aim to estimate (2.5) and (2.6) or (2.7), and this is routinely done when models
are fully specified or assumptions are made about higher order moments in estimating functions.
3 ASYMPTOTIC BEHAVIOUR UNDER A DEPENDENT OBSERVATION SCHEME
3.1 PRELIMINARY DERIVATIONS FOR A COMPLETE AND AVAILABLE CASE ANALYSIS
The derivations in Section 2.4 gave the joint distribution of Y |X; however, not all K transfusions are
necessarily observed when individuals are followed for a fixed period of time. Given X and V , the
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joint probability for the first K responses and the event that all are observed over [1, C] is
P (Y, TK ≤ C|X, V ) =
C∑
TK=K
∑
Z¯(TK)
P (Z(1) = 1, . . . , Z(TK) = 1, Y1, . . . , YK |X, V ) (3.1)
where
∑
Z¯(TK)
means to sum up over all realizations Z(2), . . . , Z(TK − 1) subject to the constraint∑TK−1
t=2 Z(t) = K − 2, where we omit the terms Z(1) and Z(TK) because transfusions occur on day
1 with probability one and Z(TK) = 1 with probability one by definition. The joint probability in the
summand of (3.1) is
TK∏
t=2
[
P (Z(t)|Y¯ (t), Z¯(t), X, V )P (YN(t)|Y¯ (t), Z(t) = 1, Z¯(t), X, V )Z(t)
]
× P (Y1|Z(1) = 1, X, V )P (Z(1) = 1|X, V )
which can be expressed as
TK∏
t=2
[
λ(t|H¯(t))Z(t)(1− λ(t|H¯(t)))1−Z(t) · (µYN(t)N(t) (1− µN(t))1−YN(t))Z(t)
]
µY11 (1− µ1)1−Y1
where µk(X, V ) = P (Yk = 1|X, V, Y¯k) and we suppress the dependence of µk(X, V ) on X and V
above; see Section 4.1 for details on the form of µk(X, V ).
The probability that at least K transfusions are observed over [1, C] is then simply
P (TK ≤ C|X, V ) =
∑
y1
· · ·
∑
yK
P (Y1 = y1, . . . , YK = yK , TK ≤ C|X, V ) , (3.2)
and the conditional joint probability mass function for Y given they were observed over [1, C] is then
P (Y1, . . . , YK |TK ≤ C,X, V ) = P (Y1, . . . , YK , TK ≤ C|X, V )∑
y1
· · ·∑yK P (Y1 = y1, . . . , YK = yK , TK ≤ C|X, V ) . (3.3)
Because we do not wish to assess the treatment effect in a model controlling for V , we average over
V as in Section 2. The difference here is that for the Kth transfusion, we require the distribution of
V given TK ≤ C and X , or equivalently P (V |TK ≤ C,X). Thus, for the Kth transfusion, we use
P (V |TK ≤ C,X) = P (TK ≤ C|X, V )P (V )∑1
v=0 P (TK ≤ C|X, V = v)P (V = v)
(3.4)
where X and V are independent by randomization.
If analyses are restricted to individuals who experienced all K transfusions, then taking (3.3) and
(3.4), we obtain the relevant joint distribution as
P (Y1, . . . , YK |TK ≤ C,X) = EV |TK≤C,X [P (Y1, . . . , YK |TK ≤ C,X, V )] (3.5)
from which we can obtain P (Yk = 1|TK ≤ C,X), k = 1, 2, . . . , K. Moreover,
COV(Yj, Yk|TK ≤ C,X) = P (Yj = 1, Yk = 1|TK ≤ C,X)
−P (Yj = 1|TK ≤ C,X)P (Yk = 1|TK ≤ C,X) ,
for j < k ≤ K, and the odds ratio associating Yj and Yk given TK ≤ C and X is then
P (Yj = 1, Yk = 1|TK ≤ C,X)/P (Yj = 0, Yk = 1|TK ≤ C,X)
P (Yj = 1, Yk = 0|TK ≤ C,X)/P (Yj = 0, Yk = 0|TK ≤ C,X) . (3.6)
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This odds ratio is estimable in likelihood analyses or analyses based on generalized estimating equa-
tions [21, 22].
A more common approach to analysis would be to use all available information from individuals
such that individuals with K† ≤ K transfusions observed over [1, C] would contribute data for the
K† transfusions. In this case, for the kth transfusion (k ≤ K†), the marginal probability of success is
P (Yk = 1|Tk ≤ C,X) = EV |Tk≤C,X [P (Yk = 1|Tk ≤ C, V,X)] , (3.7)
and so, it is dependent on k. For j < k ≤ K†,
COV(Yj, Yk|Tk ≤ C,X) = P (Yj = 1, Yk = 1|Tk ≤ C,X)
−P (Yj = 1|Tk ≤ C,X)P (Yk = 1|Tk ≤ C,X)
and the corresponding odds ratio is
P (Yj = 1, Yk = 1|Tk ≤ C,X)/P (Yj = 0, Yk = 1|Tk ≤ C,X)
P (Yj = 1, Yk = 0|Tk ≤ C,X)/P (Yj = 0, Yk = 0|Tk ≤ C,X) . (3.8)
A key point here is that if the “true” odds ratio for the association conditional on X is given by
(2.7), the exchangeable odds ratio (3.6) is being estimated in an analysis restricted to individuals with
K transfusions. When available data are used, the odds ratio associating Yj and Yk (j < k) depends on
k, as suggested by (3.8), and most standard methods of analyses would not yield consistent estimates
of this quantity or the underlying association. Finally, note that the derivations thus far have been
based on the assumption that all individuals were observed over the entire treatment period (1, C].
When the duration of follow-up varies between individuals, the corresponding limiting values of
estimators are more complicated to derive and will depend on the distribution of the duration of
observation.
3.2 UNWEIGHTED AVAILABLE CASE ANALYSIS
If analyses are directed at assessing the probability of response and associated treatment effects by
transfusion number, one could fit a binary model with the following estimating equation:
I(Tk ≤ C)D′k [VAR(Yk|X)]−1 (Yk − pik(X)) (3.9)
where pik(X) = expit(θk0 + θk1X) is the marginal mean for the kth transfusion given X only, Dk =
dpik(X)/dθk is a 2 × 1 vector where θk = (θk0, θk1)′, and VAR(Yk|X) = pik(X)(1 − pik(X)). With
complete observation of all K responses, the I(Tk ≤ C) term is absent, and estimators of θk for
different values of k are all estimating θ0 and θ1 given in (2.5). The condition I(Tk ≤ C) is implicitly
present in the “available case” analysis for the kth transfusion. Thus with an unweighted available
case analysis, we are estimating
θ∗k0(ζ, ϑ, ϕ, ν) = logit(P (Yk = 1|Tk ≤ C,X = 0)) (3.10)
θ∗k1(ζ, ϑ, ϕ, ν) = logit(P (Yk = 1|Tk ≤ C,X = 1))− θ∗k0(ζ, ϑ, ϕ, ν)
The limiting values in (3.10) are also the limiting values under a generalized estimating equation
analysis with a working independence assumption and vectors of regression coefficients that vary by
response number.
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3.3 WEIGHTED ANALYSIS BASED ON A MARGINAL MODEL
Suppose we fit a logistic model with the following contribution to the estimating function from an
individual who satisfies the condition that their kth transfusion occurs over [1, C]:
Uk(θk;αk) =
I(Tk ≤ C)
P (Tk ≤ C|X, V ;αk)D
′
k[VAR(Yk|X)]−1 (Yk − pik(X)) (3.11)
where pik(X) = expit(θk0 + θk1X) is the marginal mean for the kth transfusion given X only and
P (Tk ≤ C|X, V ;αk) is the probability that this transfusion is observed given (X, V ) is used to
specify the unstabilized weights. The marginal response model is the kind of model we would fit if
we were interested in assessing trends in response over time, or looking at how the effect of treatment
varies by transfusion number. It is marginal in the sense that it does not involve conditioning on any
variables other than the treatment variable, but the inverse probability weight ensures that consistent
estimates are obtained. The term “marginal” is also appropriate because it may be viewed as based
on one of the two potential outcomes in the framework of counterfactuals [23]. At the suggestion of
a referee, in Appendix A, we recast this problem within the framework of counterfactual outcomes
for readers aquainted with this theory and to justify our use of the term marginal structural model
[23]. Although marginal structural models are often used to deal with dynamic response-dependent
treatment selection [24–26], we show the model here to be simple, robust, and convenient to use. In
practice of course, we must estimate the weights, but we obtain consistent estimates of θk from (3.11)
when αk is replaced with a
√
n−consistent estimate α̂k. Appendix B outlines how one can estimate
weights and compute suitable variance estimates.
The appeal of (3.11) is that the solution is consistent for θ given by (2.5), so the use of the inverse
probability weights eliminates any spurious evidence of a trend in the mean response or treatment
effects over time. It has the usual form of an inverse probability weighted estimating function used in
monotone missing longitudinal data with observation-specific weights proportional to the inverse of
the probability; the observation is realized given observed data. A key difference is that in the present
setting, the observations are not necessarily “missing”, in the same sense they are in longitudinal
studies with repeated measures designs, but rather could be observed if the period of observation
were longer. It is apparent from the form of the weight in (3.11) that the weighting aims to create a
pseudosample mimicking the sample at the time of randomization when X ⊥ V ; in equation (A.2),
the term P (X|V, Tk < C) is analogous to the probability of exposure used to inverse weight in
observation studies. We comment more on this in Section 5.
If an analysis is planned on the basis of generalized estimating equations, we may adopt a marginal
mean response model logit(P (Yk = 1|X)) = θk0 + θk1X . We may allow the intercept to vary with
transfusion number as well as the effect of treatment, which would be particularly appealing if interest
was in the assessment of trend. Alternatively, a parsimonious way of assessing treatment effects is
to constrain θk1 = θ1, so there is a single odds ratio for treatment. For generality, we let θ denote
the vector of parameters in the mean model, which here is of dimension p. We remark that it is
unlikely that the correct covariance matrix would be specified given the dependence of the covariance
on the number of transfusions and suppose a working independence assumption is made, in part for
simplicity but also because there can be convergence issues when working covariance matrices are
grossly misspecified [27,28]. In this case, each individual would have a contribution to an estimating
function of the form
U(θ;α) = D′V−1∆ (Y − pi(X)) = 0
where pi = pi(X) = E(Y |X) is aK×1 vector of marginal means with pi(X) = (pi1(X), . . . , piK(X))′,
V = diag(pik(1−pik), k = 1, . . . , K) is the K×K covariance matrix, D = dpi(X)/dθ is a K×p ma-
trix of derivatives, ∆ = diag(I(Tk ≤ C)/P (Tk ≤ C|X, V ;αk), k = 1, 2, . . . , K) is a weight matrix,
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and α = (α1, . . . , αK)′ is the full vector of parameters for the weights. Under the working indepen-
dence assumption, it is clear that the previous arguments for consistency hold in this setting with the
indicated weights. The denominators of the entries in the weight matrix ∆ are key to ensuring that
consistent estimators of θ are obtained, but we can use stabilized weights [29] to improve efficiency.
In this case, the diagonal entries in ∆ may be replaced by I(Tk ≤ C)P (Tk ≤ C)/P (Tk ≤ C|X, V ),
or I(Tk ≤ C)P (Tk ≤ C|X)/P (Tk ≤ C|X, V ), k = 1, 2, . . . , K; we consider the latter in the next
section.
4 EMPIRICAL STUDIES AND AN APPLICATION
4.1 SIMULATION STUDIES
Here, we consider some particular parameter settings to study the factors governing the development
of spurious trends from the selection effects. We let ϑ0 = 0 in (2.2), ϑ1 = log(0.5) to correspond to a
50% reduction in the odds of success with the experimental product, ϑ2 = log(0.2) to reflect the effect
of V as increasing the odds of success, and ϑ3 = 0 and log(5) to correspond to no effect modification
and a strong effect modifying role of V . Preisser et al. [30] give an algorithm for modeling multi-
variate binary data with a given marginal mean and covariance structure on the basis of conditional
probabilities. Let µ1(X, V ) = P (Y1 = 1|X, V ) = pi1(X, V ) and µk(X, V, Y¯k) = P (Yk = 1|X, V, Y¯k)
where k = 2, . . . , K denote conditional probabilities. Let
Σk(X, V ) =

VAR(Y1|X, V ) COV(Y1, Y2|X, V ) . . . COV(Y1, Yk−1|X, V )
COV(Y2, Y1|X, V ) VAR(Y2|X, V ) . . . COV(Y2, Yk−1|X, V )
...
...
...
COV(Yk−1, Y1|X, V ) COV(Yk−1, Y2|X, V ) . . . VAR(Yk−1|X, V )

denote the (k − 1) × (k − 1) covariance matrix of the subvector (Y1, . . . , Yk−1)′ given X and V . If
we let
ψ∗k(X, V ) = (COV(Y1, Yk|X, V ), COV(Y2, Yk|X, V ), . . . , COV(Yk−1, Yk|X, V ))′ ,
be a (k − 1)× 1 vector and
ψk(X, V ) = [Σk(X, V )]
−1ψ∗k(X, V ) ,
then the conditional probability of success for the kth transfusion given X , V , Y¯k is
µk(X, V ) = P (Yk = 1|X, V, Y¯k) = pik(X, V ) +
k−1∑
j=1
ψj(X, V )(Yj − pij(X, V )) ,
k = 2, . . . , K, and we obtain
P (Y1, . . . , YK |X, V ; θ) =
K∏
j=1
µj(X, V )
Yj(1− µj(X, V ))1−Yj .
We followed this algorithm to generate the responses to the first K transfusions, and focus on the
setting where ϕ = 1; other values of the association parameter yielded similar results, which we do
not report here. We next address the generation of the transfusion times over a treatment period of
C = 10 days, and suppose K = 5 transfusions are to be analysed. For the transfusion process, we
consider (2.1) with ζ3 = ζ4 = 0, set ζ2 = log(0.5), so a transfusion on the previous day reduces the
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odds of needing one on a current day, and set ζ0 and ζ1 such that P (N(C) ≥ K|V = 0) = 0.6 and
logit(P (N(C) ≥ K|V = 1))− logit(P (N(C) ≥ K|V = 0)) = log(0.1). This gives ζ0 = 0.624 and
ζ1 = −0.953. We let P (V = 1) = 0.5 and P (X = 1) = 0.5. We simulated one thousand data sets
with samples of n = 2000 each.
Table 1 summarizes the results where the asymptotic bias is defined as the parameters in (3.10)
minus the corresponding parameters in (2.5). The case with exp(ϑ3) = 1 is in the top half, and here,
we see the unweighted analysis yields estimates consistent for the limiting values derived in Section
3; we report the empirical biases as the mean estimate minus the true value. Because we know
the true parameter values, we can conduct weighted analyses with the true weights, and we report
the corresponding results in the second set of columns. These demonstrate that inverse weighting
yields estimators with negligible empirical bias. When weights are estimated on the basis of stratified
discrete time survival models, the empirical biases are again negligible and as one would expect, there
is a very slight decrease in the empirical standard errors. When stabilized weights are used, the results
are again very similar to the nonstabilized weights. Table 2 gives analogous results for the case in
which subjects are randomly censored over the course of the treatment period. Because of variable
follow-up, the asymptotic calculations in Section 3 no longer apply, and the empirical biases for the
naive analyses are slightly different from the asymptotic biases computed on the basis of common
follow-up. Again, the use of true or estimated weights reduces the bias to a negligible level. In this
setting, however, the reduction in the asymptotic and empirical standard errors from use of stabilized
weights is much more substantial because of the greater variation in the weights employed (i.e., some
of the weights are smaller in this setting because the kth transfusion is less likely to be experienced
within a shorter period of follow-up).
4.2 APPLICATION TO A PLATELET TRANSFUSION TRIAL
Here, we report on an illustrative analysis of the Mirasol trial discussed in Section 1.2 to compare the
effectiveness of pathogen-inactivated platelets to standard platelets in patients with chemotherapy-
induced thrombocytopenia. The cumulative distribution function for the 1 h CCI is given by transfu-
sion number in Figure 2 where it can be seen that the median CCI decreases by transfusion number
and the empirical probability of success (CCI > 7500) decreases with transfusion number.
The available potential confounding variables we adjusted for in the inverse probability weight
were treatment, sex, ABO group, baseline platelet count (above median of 43,500 or not), and systolic
(above median of 120 or not) and diastolic (above median of 70 or not) blood pressure. Proportional
odds regression models were used for each transfusion number with individuals censored at 28 days
or the time of withdrawal. We considered stabilized weights with the numerators given by P (Tk ≤
C|X). Figure 4 gives the estimated probability of a successful transfusion by transfusion number for
reference patients, with the solid circles corresponding to naive estimates based on
n∑
i=1
I(Tik ≤ Ci)Yik(1−Xi)Wik/
n∑
i=1
I(Tik ≤ Ci)(1−Xi)Wik
where Wik = 1. We present the inverse weighted estimates as diamonds and are computed them
on the basis of stabilized weights with Wik = P (Tik ≤ Ci|Xi)/P (Tik ≤ Ci|Xi, Vi). It is readily
apparent that the suggestion of a trend based on the unweighted estimates is greatly attenuated or
eliminated with the weighted analyses. Figure 5 gives the box plots (log10 scale) of the distribution
of stabilized weights, where it can be seen that there is greater variation in the weights for higher
transfusion numbers.
Next, a response model of the form
logit(pi(X)) = θk0 + θ1X (4.1)
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was fit using generalized estimating equations under a working independence covariance structure.
The common regression coefficient in (4.1) was used to synthesize the evidence of a treatment effect
over all transfusions. An unweighted analysis yielded θ̂1 = −0.73 (s.e.(θ̂1) = 0.38) giving an odds
ratio estimate of 0.48 (95% CI: (0.23,1.02); p−value = 0.056). The inverse probability weighted
generalized estimating equation gave θ˜1 = −0.84 (s.e.(θ˜1) = 0.40) and a slightly smaller estimate of
the odds ratio at 0.43 (95% CI: (0.20,0.94); p−value = 0.034). There are at most two individuals
with particularly large weights contributing to the analyses of the sixth and seventh transfusions, so
we conducted a sensitivity analysis in which weights were truncated [31] at 10 and then 5, and the
conclusions did not materially change (θ˜ = −0.85 and −0.86, respectively).
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Figure 4: Unweighted and stabilized weighted estimates of the probabilities of success for patients in
the reference group.
5 DISCUSSION
This article highlighted the need for care when analysing responses to administration of therapeutic
interventions to treat episodic conditions. There are numerous clinical settings where the observations
we make are relevant, and the findings should lead to alternative designs or frameworks for analysis.
Examples of such settings include migraine studies, which involve randomizing patients to an exper-
imental therapy or standard care, and interest lies in assessing the effectiveness of the experimental
intervention relative to standard care [32,33]. Studies of new rescue medications for exacerbations in
chronic bronchitis aim to assess effects on the severity or duration of symptoms [34, 35]. In studies
of therapies for erectile dysfunction, trials aim to evaluate treatment effects based in part on success
rates in attempts at sexual intercourse [36, 37]. The distinguishing feature of these settings is that
past responses may alter the probability of observing future responses by changing the distribution
of times between critical events (e.g., exacerbations in respiratory disease or need for transfusions in
thrombocytopenia).
Although data resulting from such designs have similar features to repeated measures data, there is
an underlying stochastic mechanism, which leads to the need for transfusions, and this can mean that
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Figure 5: Box plots (log10 scale) for the distribution of stabilized weights (P (Tk ≤ C|X)/P (Tk ≤
C|X, V )) for patients in the reference group (R) and experimental group (E).
naive estimators are consistent for uninterpretable parameters. There are subtle issues related to the
following: (i) heterogeneity in baseline platelet levels between patients; (ii) between patient hetero-
geneity in the response rates to transfusions; and (iii) the relationship between response to transfusion
and the time of the next transfusion, all of which complicate analyses. Whether it is sensible to con-
ceptualize a “response rate” across all transfusions, or indeed a common treatment effect across all
transfusions, warrants careful consideration. The interest in simple summary measures of interven-
tion effects motivated us to adopt a framework where the true response rates did not change over time.
Even in this setting, patterns or trends may be apparent from naive analyses, but these are spurious and
a reflection of heterogeneity in need for transfusions and the consequent selection effects. This work
was motivated in part by apparent trends in response to transfusion by transfusion number. Although
clinical researchers have suggested there may be a decreasing effect of transfusions over time [19],
the models we present here offer alternative explanations.
There is a large literature on methods for incomplete longitudinal data. The focus of this work
has been primarily on studies where follow-up assessments are scheduled at particular visit times
and individuals may withdraw from a study before completing all of these assessments (i.e., mono-
tone missing data problems). Inverse weighted estimating functions are perhaps most widely adopted
for semiparametric analyses, and much of the literature is devoted to “missing at random” mecha-
nisms [38]. In this context, these weights are estimated by modeling the conditional probability of
remaining in the study until the next visit given completion of the current visit and the observed “his-
tory” [39, 40]. Less attention has been directed to the setting in which no visit schedule is planned
and assessments happen in a “fully stochastic” fashion. One exception is Lin et al. [41] who con-
sider intensity-based models for a continuous time visit process and estimating functions for marginal
semiparametric models of the responses obtained upon assessment, which are inverse weighted by the
intensity of the visit process. Zhu et al. [42] extend this methodology to deal with time-varying re-
gression coefficients for the response model. Sun et al. [43,44] develop joint models for the response
process and assessment process through the used of shared frailty models. Chen et al. consider joint
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models for the observation process and responses in the context of progressive models in continuous-
time [45] and discrete-time [46] processes, respectively.
The approach we describe is somewhat similar in spirit with these approaches, but has key differ-
ences. First, rather than modeling the visit intensity (the instantaneous conditional probability of an
assessment at time t given the history), we model the (not instantaneous) probabilities that a particular
intervention (kth) will be required within the predetermined window of observation given covariates.
Second, we adopt marginal models in the sense that we fit these models separately for the kth and
`th assessments; that is, we do not make use of the fact that the kth assessment cannot happen if the
(k − 1)st assessment has not yet happened for reasons of robustness. This is similar to the marginal
approach of Pepe and Cai [47], which offers a robust approach to analysis. Third, we obtain further
robustness with discrete covariates in which case one may stratify on the covariate values; we have
demonstrated empirically that this performs well. Fourth, because we model the distributions of the
times to the interventions rather than intensities, we do not need to adopt any kernel smoothing of
baseline intensities. Finally, the observation process is fundamentally different in the present setting
because it relates to a need for an intervention and so is directly tied to the underlying disease process;
in much of the previous work, there are latent responses that are unobserved between assessments.
Inverse probability weighting is essential for fitting marginal models because these can be used to
obtain estimates of response rates and treatment effects for second and subsequent transfusions, which
are compatible with the estimates from the first transfusion. In practice, the weights for such analyses
are often difficult to specify, and although model diagnostics offer one approach for assessment of the
model for the weights, it is clear that this approach to the analysis is within realm of observational
analyses and so will not furnish evidence of the same level as more simple randomized trials. An
alternative approach to the analysis would be to match, stratify, or otherwise control for the propensity
score at each transfusion [48]. This would require developing different propensity scores for each
transfusion and would yield an estimate of the treatment effect conditional on the associated factors,
which has a different interpretation than the estimate from the marginal structural model [49].
In some randomized trials, it is possible to randomize patients each time an intervention (e.g.,
transfusion) is required [50, 51], and this addresses the effect of confounding variables. There re-
mains a subtle issue of whether the probability of response, or the effect of the intervention, is stable
over successive transfusions, but we have assumed this in our current formulation; when this is not
plausible, it is even more challenging to think about suitable objects of inference and analysis strate-
gies.
APPENDIX A REFORMULATION OF THE PROBLEM IN TERMS OF COUNTER-
FACTUALS
Discussions regarding causal inference often involve the conceptualization of counterfactual or “po-
tential” outcomes. Although the need to adopt this framework is somewhat contentious [52], many
view it to be a useful construct [53], and Robins [23] defines marginal structural models in terms
of counterfactuals. Herein, we make some related remarks at the suggestion of a referee. Adapting
the notation of Section 2.1, we let Z [x=1](t) and Z [x=0](t) denote the indicators that an individual
would receive a transfusion on day t if they were randomized to the experimental or standard platelet
product respectively; the counterfactual transfusion history at time t is given by Z¯ [x](t). We let Y [x]k
be the indicator that the kth transfusion under treatment x yields a successful response and let the
histories in discrete time and in terms of transfusion number be Y¯ [x](t) and Y¯ [x]k , respectively. Under
the consistency assumption [24], the observed transfusion and outcome processes correspond to the
counterfactuals for the treatment actually received, that is, Z(t) = Z [x](t) and Yk = Y
[x]
k if X = x.
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The response model in (2.4) is compatible with the marginal structural model
P (Y
[x]
k = 1) = expit(θ
†
0 + θ
†
1x) . (A.1)
Because this is a model for the potential outcome Y [x]k the parameter θ
†
1 has a causal interpretation. In
particular exp(θ†1) is the causal odds ratio for a successful response when an individual is given the
experimental platelet product versus the standard. The model in (A.1) can be extended to allow the
parameters θ†0 and/or θ
†
1 to depend on transfusion number; when the intercept depends on k, we denote
this by θ†k0 and are stratifying on transfusion number, and when the treatment coefficient depends on
k, we write θ†k1 to allow the treatment effect to vary by transfusion number.
Although treatmentX is randomized and therefore unconfounded, the probability of observing the
kth transfusion before the end of follow-up on day C may not be the same in each treatment arm. We
handle this administrative censoring by inclusion of weights wk(t) = [P (Tk ≤ C|X, V )]−1 in (3.11).
Under the assumptions of positivity and no unmeasured confounders [25] and assuming the model for
P (Tk ≤ C|X, V ) is correctly specified, adjustment via these weights allows us to estimate the causal
odds ratio for experimental versus standard platelet products for the setting in which subjects in each
treatment arm are at the same risk of receiving k transfusions.
To see this, we now show that (3.11) is an unbiased estimating function for θ by taking its expec-
tation. First note that
P (Tk ≤ C|X,V ) = P (X|V, Tk ≤ C)P (Tk ≤ C|V )P (V )
P (X)P (V )
= 2 · P (X|V, Tk ≤ C)P (Tk ≤ C|V ) . (A.2)
Thus, we can write
Uk(θk;αk) =
I(Tk ≤ C)
2 · P (X|V, Tk ≤ C)P (Tk ≤ C|V )D
′
k[VAR(Yk|X)]−1 [Yk − pik(X)]
We can show that the first element of this estimating equation has expectation zero by first taking the
expectation with respect to Yk|X, V, Tk ≤ C to obtain
I(Tk ≤ C)
2 · P (X|V, Tk ≤ C)P (Tk ≤ C|V ) [E(Yk|X, V, Tk ≤ C)− pik(X)] .
Next, we take the expectation with respect to X|V, Tk ≤ C
1∑
x0=0
I(Tk ≤ C)
2 · P (X = x0|V, Tk ≤ C)P (Tk ≤ C|V ) [E(Yk|X = x0, V, Tk ≤ C)− pik(x0)]P (X = x0|V, Tk ≤ C)
=
1∑
x0=0
I(Tk ≤ C)
2 · P (Tk ≤ C|V ) [E(Yk|X = x0, V, Tk ≤ C)− pik(x0)] .
Next, we take the expectation with respect to I(Tk ≤ C)|V or equivalently Ik|V where Ik = I(Tk ≤
C). This gives
1∑
i0=0
1∑
x0=0
i0
2 · P (Ik = i0|V ) [E(Yk|X = x0, V, Ik = i0)− pik(x0)]P (Ik = i0|V )
=
1∑
x0=0
1
2
[E(Yk|X = x0, V )− pik(x0)] ,
because when i0 = 0, there is no contribution. The net effect of the cancellation of P (Ik = 1|V ) pre-
viously is to “average” over Ik in the “setting” where the probability of observing the kth transfusion
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is 1. This is the setting we would be working in if we did not have a finite period of observation, and
is the setting compatable with the specification of the marginal response model. Hence, we remove
the condition Ik = 1. Finally, we can take the expectation with V as
1∑
v0=0
1∑
x0=0
1
2
[E(Yk|X = x0, V = v0)− pik(x0)]P (V = v0) =
1∑
x0=0
1
2
[E(Yk|X = x0)− pik(x0)] = 0
The estimating equation for the previous marginal structural model can be fit through use of
weighted generalized estimating equations as given in (3.11); large sample properties of the resulting
estimators are discussed in Appendix B.
APPENDIX B DERIVATION OF ASYMPTOTIC VARIANCE FROM WEIGHTED ANAL-
YSES
The following derivation is based on the general theory layed out by Newey and McFadden [54] and
Robins et al. [39]. Here, we introduce a subscript i to index individuals because we must compute
empirical averages over individuals for variance estimation. Let Ci denote the last observation time
for individual i and Ci(t) = I(t ≤ Ci) and C†ik(t) = I(t ≤ Tik) and C¯ik(t) = Ci(t)C†ik(t). Let Tik
denote the time of the kth transfusion for individual i, and let Fk(t|x, v) = P (Tk > t|x, v;α). Then,
suppose we let
pk(t|x, v) = P (Tk = t|Tk ≥ t, x, v)
be the discrete hazard for an individual with covariate vector (x, v) at t ≥ k, and
logit(pk(t|x, v)) = u′k(t)αk(x, v)
where uk(t) = (I(t = k+ 1), . . . , I(t = C)) is a (C− k+ 1)× 1 vector of time-dependent indicators
αk(x, v) = (αkk(x, v), . . . , αkC(x, v))
′ is a vector of coefficients where αkk(x, v) = logit(pk(k|x, v))
and αk`(x, v) = logit(pk(`|x, v))− αkk(x, v), ` = k + 1, . . . , C. Then
F̂k(t|x, v) =
t∏
s=k
(1− p̂k(s|x, v)) . (B.1)
Let dNik(t) = 1 if kth transfusion occurs on day t for individual i and zero otherwise. Consider
the estimating function
Sikr(αkr(xi, vi)) =
∑
x
∑
v
C¯ik(r) · (dNik(r)− pik(r|x, v)) · I(x = xi, v = vi)
and the vector
Sik(αk(xi, vi)) =

Sikk(αk(xi, vi))
Sik,k+1(αk(xi, vi))
SikC(αk(xi, vi))

Setting Sik(αk(xi, vi)) = 0 gives α̂k(xi, vi)), which can be plugged in to get estimate (B.1).
The derivation of the asymptotic variance of θ̂k from the weighted estimating equation is as fol-
lows. Let ψk = (α′k, θ
′
k)
′. Let us proceed first by just considering the weighted estimating function
for the response to the kth transfusion
Gk(ψk) =
n∑
i=1
Gik(ψk) =
(
Sik(ψk)
Uik(ψk)
)
=
n∑
i=1
(
Sik(αk)
Uik(θk, αk)
)
.
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Then
Gk(ψ̂k) = Gk(ψk) +
dGk(ψk)
dψk
(ψ̂k − ψk) + op
(
1√
n
)
and
√
n (ψ̂k − ψk) = −
[
1
n
dGk(ψk)
dψk
]−1 [
1√
n
Gk(ψk)
]
+ op(1) (B.2)
where
dGk(ψk)
dψ′k
=
[
dSk(αk)/dα
′
k dSk(αk)/dθ
′
k
dUk(ψk)/dα
′
k dUk(ψk)/dθ
′
k
]
.
Note
1
n
dGk(ψk)
dψk
=
1
n
n∑
i=1
dGik(ψk)
dψk
which converges in probability to E(dGik(ψk)/dψk) where
E
(
dGik(ψk)
dψk
)
=
[
E(dSik(αk)/dα
′
k) 0
E(dUik(ψk)/dα
′
k) Γ(ψk)
]
where Γ(ψk) = E(dUik(ψk)/dθ′k). From (B.2) then
√
n (ψ̂k − ψk) converges to
−
[
E
(
dGik(ψk)
dψ′k
)]−1 [
1√
n
(
Sk(αk)
Uk(ψk)
)]
= − 1√
n
[
[E(dSik(αk)/dα
′
k)]
−1 Sk(αk)
−Γ−1(ψk)E(dUik(ψk)/dαk) [E(dSik(αk)/dα′k)]−1 Sk(αk) + Γ−1(ψk)Uk(ψk)
]
Thus,
√
n (θ̂k − θk)→ − 1√
n
Γ−1(ψk)
{
Uk(ψk)− E
(
dUik(ψk)
dα′k
)[
E
(
dSik(αk)
dα′k
)]−1
Sk(αk)
}
which converges in distribution to
N(0,Γ−1(ψk)E [Qik(ψk)Q′ik(ψk)]
[
Γ−1(ψk)
]′
)
where
Qik(ψk) = Uik(ψk)− E
(
dUik(ψk)
dα′k
)[
E
(
dSik(αk)
dα′k
)]−1
Sik(αk) .
As is commonly carried out, we estimate the requisite expectations with their empirical counterparts,
and hence
âsvar(
√
n(ψ̂k − ψk)) = Γ̂−1(ψ̂k)B̂k(ψ̂k)
[
Γ̂−1(ψ̂k)
]′
where
Γ̂(ψ̂k) =
1
n
n∑
i=1
dUik(ψk)
dθ′k
∣∣∣∣
ψk=ψ̂k
,
B̂k(ψ̂k) =
1
n
n∑
i=1
Q̂ik(ψk)Q̂
′
ik(ψk)
∣∣∣∣
ψk=ψ̂k
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and
Q̂ik(ψk) = Uik(ψk)−
[
1
n
n∑
i=1
dUik(ψ)
dα′k
][
1
n
n∑
i=1
dSik(αk)
dα′k
]−1
Sik(αk) .
The derivation of the asymptotic variance of the estimates of the parameters in the marginal struc-
tural model obtained by inverse weighting is similar to Hernan et al. [25].
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